Skip to main content
SciBX: Science-Business eXchange
As published Thursday, October 16, 2014

  • Cover Story: DisABLing imatinib

    By Kai-Jye Lou, Senior Writer

    DisABLing imatinib

    Mutations in BCR-ABL tyrosine kinase have long been associated with resistance to Gleevec imatinib, but they only account for about half of all cases. University of Massachusetts researchers have shown that upregulation of protein kinase Ch could be an alternative cause and might provide a new target for bypassing resistance.1 But blocking the downstream signaling components could be easier than creating specific inhibitors of the relatively unexplored protein kinase C isoform.

    Full Article


  • This Week in Therapeutics

    Promoting DNA repair to prevent progression in BRCA1+ cancers; scavenging gamma-ketoaldehydes to reduce blood pressure; enhancing ML4 activity to treat muscular dystrophies; and more...

  • more therapeutics news
  • This Week in Techniques

    Patient-derived prostate organoids as prostate cancer models; a 3D matrix platform for generating mAbs to treat breast cancer; GSN as a marker for cisplatin sensitivity and patient survival in ovarian cancer; and more...

  • more techniques news
Subscribe Now
Free Trial